The need for an advanced understanding of lipidology structure and function in healthcare is growing. Understanding lipoprotein function may provide valuable insights into an individual's lipid profile, aiding in the assessment of cardiovascular risk and guiding interventions above and beyond the standard lipid panel.
Apolipoprotein ApoC2 plays a pivotal role in lipid metabolism and cardiovascular health by
promoting hydrolysis of triglycerides within circulating lipoproteins. As an essential cofactor for lipoprotein lipase (LPL), ApoC2 orchestrates the breakdown of triglyceride-rich lipoproteins into free fatty acids, facilitating their uptake by various tissues for energy utilization or storage.
Understanding the multifaceted roles of ApoC2 not only sheds light on lipid metabolism intricacies but also unveils its potential as a therapeutic target for metabolic disorders and cardiovascular diseases.
Apolipoprotein C2 (ApoC2) is a small protein component found primarily in triglyceride-rich lipoproteins like chylomicrons and very low-density lipoproteins (VLDL), as well as on HDL particles during fasting. [14.] It is made in the liver, the intestines, and by macrophages.
Its primary role lies in facilitating the breakdown of triglycerides by acting as a cofactor for lipoprotein lipase (LPL), an enzyme crucial for the hydrolysis of triglycerides into free fatty acids and glycerol. [7.]
This process occurs in the circulation where ApoC2 activates LPL, enabling it to bind to lipoprotein particles and initiate the lipolysis process. By promoting lipolysis of triglycerides, ApoC2 enhances the removal of triglyceride-rich lipoproteins (TRLs) and their remnants from the bloodstream. [7., 14.]
Hepatic expression of ApoC2 involves its secretion into the plasma, where it acts to enhance triglyceride hydrolysis of very low-density lipoproteins (VLDL) and chylomicrons for energy delivery or storage. [14.]
The APOC2 gene in the liver is controlled by liver-specific hepatic control regions, which respond to metabolic cues such as bile acids.
ApoC2 is also expressed in macrophages, particularly those within arterial lesions, where it likely aids in delivering triglycerides (TG) to these metabolically active cells. This function may contribute to atherosclerosis. [14.]
Macrophage-specific expression of APOC2 may increase local LPL activity and promote cholesterol efflux from foam cells in arterial walls. [14.] ApoC2 regulation in macrophages involves multiple interactions, suggesting a complex regulatory network specific to macrophages. [14.]
ApoC2 created in the intestines is incorporated into chylomicrons, where it aids in the delivery of triglycerides to tissues.
Understanding the clinical significance of ApoC2 levels involves understanding its role in triglyceride metabolism.
ApoC2 deficiency, a rare condition, is clinically significant due to its association with severe hypertriglyceridemia and the increased risk of pancreatitis. Diagnosing apoC2 deficiency requires careful evaluation to distinguish it from other causes of hypertriglyceridemia, including polygenic and secondary factors such as diabetes, hypothyroidism, and certain medications. [14.]
Clinical manifestations typically appear during childhood or adolescence with abdominal pain often being the initial symptom, which can progress to acute pancreatitis. Other signs may include eruptive xanthomas, lipemia retinalis, and hepatosplenomegaly.
Diagnosis involves assessing plasma triglyceride levels, which are usually markedly elevated, along with other lipid parameters. Confirmation often requires specialized biochemical or molecular analyses. Early diagnosis is crucial for implementing appropriate management strategies and family screening to mitigate the risk of complications associated with severe HTG.
In contrast, high levels of ApoC2 are associated with hypertriglyceridemia, diabetes, as well as LPL deficiency and some cancers and autoimmune conditions. [6., 13., 16.]
It is known that at high and low concentrations of ApoC2, LPL activity is decreased. [6.]
ApoC2 testing involves assessing the levels of apolipoprotein C2 (ApoC2) in the bloodstream, typically through blood serum or plasma samples. Venipuncture is commonly required. This test is commonly done in research settings.
Genetic testing to identify genetic polymorphisms of ApoC2 are also available.
More commonly, apolipoprotein testing including testing for ApoA1, ApoB, and ApoE, is available to provide additional insight into an individual’s cardiovascular risk profile.
Diet and lifestyle are the mainstays of good cardiometabolic health. Certain supplements and medications may also be considered under the guidance of a licensed healthcare practitioner.
Diets Containing Fermented Dairy Products: diets containing fermented dairy products have been shown to promote healthy lipid outcomes and increase ApoA1 levels in particular. [5., 9.]
Foods Rich in Omega-3 Fatty Acids: Fatty fish (salmon, mackerel, sardines), flaxseeds, chia seeds, walnuts all have scientific evidence of efficacy in improving lipoprotein profiles and reducing cardiovascular disease risk. [5., 9.]
Fiber-Rich Foods: Whole grains (oats, barley, quinoa), fruits (apples, berries, oranges), vegetables (broccoli, Brussels sprouts, carrots), legumes (beans, lentils) are all Mediterranean diet staples that have shown effectiveness in reducing cardiovascular disease risk. [9.]
Avoid excess sugar: diets high in sugar are highly correlated with poor cardiometabolic health outcomes, as well as elevated triglycerides. [5.]
Regular Exercise: Aerobic activities (walking, jogging, swimming), strength training, yoga, tai chi may all promote cardiovascular health. [5., 15.]
Smoking Cessation: Quitting smoking reduces oxidative stress and inflammation, contributing to improved lipid profiles. [5.]
Stress Management: Techniques such as meditation, deep breathing exercises, yoga, and mindfulness may help lower stress levels and improve overall cardiovascular health,and in some cases may also have a positive effect on lipid profiles. [11.]
Individuals should speak with their healthcare provider prior to initiating any supplement or medication therapies.
Niacin (Vitamin B3): Niacin supplementation has been shown to improve HDL cholesterol and triglyceride levels. [2., 8.]
Fish Oil: fish oil has been shown to reduce triglyceride levels and stimulate LPL activity. [12.]
Click here to compare and order tests for lipoprotein levels.
[1.] Bailey A, Mohiuddin SS. Biochemistry, High Density Lipoprotein. [Updated 2022 Sep 26]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK549802/
[2.] Brown WM, Chiacchia FS. Therapies to Increase ApoA-I and HDL-Cholesterol Levels. Drug Target Insights. 2008;3. doi:10.4137/DTI.S447
[3.] Endres K. Apolipoprotein A1, the neglected relative of Apolipoprotein E and its potential role in Alzheimer's disease. Neural Regen Res. 2021 Nov;16(11):2141-2148. doi: 10.4103/1673-5374.310669. PMID: 33818485; PMCID: PMC8354123.
[4.] Florvall G, Basu S, Larsson A. Apolipoprotein A1 Is a Stronger Prognostic Marker Than Are HDL and LDL Cholesterol for Cardiovascular Disease and Mortality in Elderly Men. The Journals of Gerontology Series A: Biological Sciences and Medical Sciences. 2006;61(12):1262-1266. doi:https://doi.org/10.1093/gerona/61.12.1262
[5.] Frondelius K, Borg M, Ericson U, Borné Y, Melander O, Sonestedt E. Lifestyle and Dietary Determinants of Serum Apolipoprotein A1 and Apolipoprotein B Concentrations: Cross-Sectional Analyses within a Swedish Cohort of 24,984 Individuals. Nutrients. 2017 Feb 28;9(3):211. doi: 10.3390/nu9030211. PMID: 28264492; PMCID: PMC5372874.
[6.] Hsu CC, Kanter JE, Kothari V, Bornfeldt KE. Quartet of APOCs and the Different Roles They Play in Diabetes. Arteriosclerosis, Thrombosis, and Vascular Biology. 2023;43(7):1124-1133. doi:https://doi.org/10.1161/atvbaha.122.318290
[7.] Jong MC, Hofker MH, Havekes LM. Role of ApoCs in Lipoprotein Metabolism. Arteriosclerosis, Thrombosis, and Vascular Biology. 1999;19(3):472-484. doi:https://doi.org/10.1161/01.atv.19.3.472
[8.] McKenney J. New Perspectives on the Use of Niacin in the Treatment of Lipid Disorders. Archives of Internal Medicine. 2004;164(7):697. doi:https://doi.org/10.1001/archinte.164.7.697
[9.] Nacarelli GS, Fasolino T, Davis S. Dietary, macronutrient, micronutrient, and nutrigenetic factors impacting cardiovascular risk markers apolipoprotein B and apolipoprotein A1: a narrative review. Nutrition Reviews. Published online August 23, 2023:nuad102. doi:https://doi.org/10.1093/nutrit/nuad102
[10.] Nazir S, Jankowski V, Bender G, Zewinger S, Rye KA, van der Vorst EPC. Interaction between high-density lipoproteins and inflammation: Function matters more than concentration! Advanced Drug Delivery Reviews. 2020;159:94-119. doi:https://doi.org/10.1016/j.addr.2020.10.006
[11.] Papp ME, Lindfors P, Nygren-Bonnier M, Gullstrand L, Wändell PE. Effects of High-Intensity Hatha Yoga on Cardiovascular Fitness, Adipocytokines, and Apolipoproteins in Healthy Students: A Randomized Controlled Study. J Altern Complement Med. 2016 Jan;22(1):81-7. doi: 10.1089/acm.2015.0082. Epub 2015 Nov 13. Erratum in: J Altern Complement Med. 2017 May;23(5):396. PMID: 26565690; PMCID: PMC4739349.
[12.] Shearer GC, Savinova OV, Harris WS. Fish oil -- how does it reduce plasma triglycerides? Biochim Biophys Acta. 2012 May;1821(5):843-51. doi: 10.1016/j.bbalip.2011.10.011. Epub 2011 Oct 25. PMID: 22041134; PMCID: PMC3563284.
[13.] Tamura N, Maejima Y, Shiheido-Watanabe Y, Nakagama S, Isobe M, Sasano T. Plasma apolipopotein C-2 elevation is associated with Takayasu arteritis. Scientific Reports. 2021;11(1):18958. doi:https://doi.org/10.1038/s41598-021-98615-3
[14.] Wolska A, Dunbar RL, Freeman LA, Ueda M, Amar MJ, Sviridov DO, Remaley AT. Apolipoprotein C-II: New findings related to genetics, biochemistry, and role in triglyceride metabolism. Atherosclerosis. 2017 Dec;267:49-60. doi: 10.1016/j.atherosclerosis.2017.10.025. Epub 2017 Oct 20. PMID: 29100061; PMCID: PMC5705268.
[15.] Yazdani R, Marefati H, Shahesmaeili A, Nakhaei S, Bagheri A, Dastoorpoor M. Effect of Aerobic Exercises on Serum Levels of Apolipoprotein A1 and Apolipoprotein B, and Their Ratio in Patients with Chronic Obstructive Pulmonary Disease. Tanaffos. 2018 Feb;17(2):82-89. PMID: 30627178; PMCID: PMC6320561.
[16.] Zhang T, Yang J, Vaikari VP, et al. Apolipoprotein C2 - CD36 Promotes Leukemia Growth and Presents a Targetable Axis in Acute Myeloid Leukemia. Blood Cancer Discovery. 2020;1(2):198-213. doi:https://doi.org/10.1158/2643-3230.bcd-19-0077